Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.11+0.06 (+1.48%)
Close on Nov 18, 2026Market cap $813.16MP/E 5.3Yield –
Arbutus Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Arbutus Biopharma's free cash flow for the twelve months ending Dec 31, 2025 was -$39.64M. For fiscal 2025 it was -$39.64M. The highest annual figure on record is $32.89M in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.64M | – |
| FY2024 | Dec 31, 2024 | -$65.03M | – |
| FY2023 | Dec 31, 2023 | -$86.94M | – |
| FY2022 | Dec 31, 2022 | -$35.87M | – |
| FY2021 | Dec 31, 2021 | -$68.34M | – |
| FY2020 | Dec 31, 2020 | -$51.67M | – |
| FY2019 | Dec 31, 2019 | -$71.60M | – |
| FY2018 | Dec 31, 2018 | -$69.00M | – |
| FY2017 | Dec 31, 2017 | -$55.90M | – |
| FY2016 | Dec 31, 2016 | -$61.88M | – |
| FY2015 | Dec 31, 2015 | -$58.67M | – |
| FY2014 | Dec 31, 2014 | -$13.48M | – |
| FY2013 | Dec 31, 2013 | -$7.46M | -122.7% |
| FY2012 | Dec 31, 2012 | $32.89M | – |
| FY2011 | Dec 31, 2011 | -$7.89M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$4.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.82M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.42M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.42M | -233.5% |
| Q4 FY2022 | Dec 31, 2022 | -$17.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.51M | – |
| Q1 FY2022 | Mar 31, 2022 | $20.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.98M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.19M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.87M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.45M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.41M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.85M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.61M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.30M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.44M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.05M | – |
| Q1 FY2018 | Mar 31, 2018 | -$20.22M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.53M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.22M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.20M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.96M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.42M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.88M | – |
See a number that looks wrong?